Kolmar Korea


Hind Wing
Agencia Lei Va Hong
Four Star
Concise Prescribing Info
Treatment of chronic HBV infection in adults w/ evidence of active viral replication & either evidence of persistent elevations in serum ALT or AST or histologically active disease.
Dosage/Direction for Use
Nucleoside inhibitor-treatment-naïve adult & adolescent ≥16 yr 0.5 mg once daily. Adult & adolescent ≥16 yr w/ history of hepatitis B viremia while receiving lamivudine or known lamivudine or telbivudine resistance substitutions rtM204I/V w/ or w/o rtL180M, rtL80I/V, or rtV173L 1 mg once daily. Adult patient w/ CrCl ≥50 mL/min Usual dose: 0.5 mg once daily. Lamivudine-refractory or decompensated liver disease: 1 mg once daily; CrCl 30 to <50 mL/min Usual dose: 0.5 mg every 48 hr. Lamivudine-refractory or decompensated liver disease: 0.5 mg once daily, or 1 mg every 48 hr; CrCl 10 to <30 mL/min Usual dose: 0.5 mg every 72 hr. Lamivudine-refractory or decompensated liver disease: 1 mg every 72 hr; CrCl <10 mL/min, hemodialysis or CAPD Usual dose: 0.5 mg every 7 days. Lamivudine-refractory or decompensated liver disease: 1 mg every 7 days. If administered on a hemodialysis day, administer Hepavance after the hemodialysis session.
Should be taken on an empty stomach: Take at least 2 hr before & after a meal.
Special Precautions
Severe acute exacerbations of hepatitis B upon discontinuation of therapy. Lactic acidosis & severe hepatomegaly w/ steatosis. Not recommended for HIV/HBV co-infected patients who are not also receiving highly active antiretroviral therapy. Patients w/ renal impairment; liver transplant recipients. Pregnancy & lactation. Ped patients. Elderly.
Adverse Reactions
Headache, fatigue, dizziness, nausea.
Drug Interactions
Co-administration w/ drugs that reduce renal function or compete for active tubular secretion may increase serum conc of either entecavir or the co-administered drug. Closely monitor for adverse events when co-administered w/ other drugs that are renally eliminated or are known to affect renal function.
MIMS Class
ATC Classification
J05AF10 - entecavir ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Hepavance tab 0.5 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in